Published in J Neurosci on August 22, 2012
CSF proteins and resting-state functional connectivity in Parkinson disease. Neurology (2015) 1.45
shRNA-Based Screen Identifies Endocytic Recycling Pathway Components That Act as Genetic Modifiers of Alpha-Synuclein Aggregation, Secretion and Toxicity. PLoS Genet (2016) 1.40
Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci (2014) 1.15
Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain (2014) 1.03
Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment. Autophagy (2014) 0.96
Rab11 modulates α-synuclein-mediated defects in synaptic transmission and behaviour. Hum Mol Genet (2014) 0.87
The associations between Parkinson's disease and cancer: the plot thickens. Transl Neurodegener (2015) 0.81
Mechanisms of alpha-synuclein action on neurotransmission: cell-autonomous and non-cell autonomous role. Biomolecules (2015) 0.81
Poststroke Induction of α-Synuclein Mediates Ischemic Brain Damage. J Neurosci (2016) 0.80
Alpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders. Front Neurosci (2016) 0.78
Mini review: linkage between α-Synuclein protein and cognition. Transl Neurodegener (2015) 0.77
α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease. Ann Clin Transl Neurol (2016) 0.77
Models of α-synuclein aggregation in Parkinson's disease. Acta Neuropathol Commun (2014) 0.77
Intracellular soluble α-synuclein oligomers reduce pyramidal cell excitability. J Physiol (2016) 0.76
Designer protein disaggregases to counter neurodegenerative disease. Curr Opin Genet Dev (2017) 0.76
Cellular Uptake of α-Synuclein Oligomer-Selective Antibodies is Enhanced by the Extracellular Presence of α-Synuclein and Mediated via Fcγ Receptors. Cell Mol Neurobiol (2016) 0.76
The Contribution of α-Synuclein Spreading to Parkinson's Disease Synaptopathy. Neural Plast (2017) 0.75
Prelysosomal Compartments in the Unconventional Secretion of Amyloidogenic Seeds. Int J Mol Sci (2017) 0.75
Synaptoimmunology - roles in health and disease. Mol Brain (2017) 0.75
Impaired c-Fos and polo-like kinase 2 induction in the limbic system of fear-conditioned α-synuclein transgenic mice. PLoS One (2012) 0.75
Exogenous Alpha-Synuclein Alters Pre- and Post-Synaptic Activity by Fragmenting Lipid Rafts. EBioMedicine (2016) 0.75
Preparation of neuronal co-cultures with single cell precision. J Vis Exp (2014) 0.75
Molecular Pathways Bridging Frontotemporal Lobar Degeneration and Psychiatric Disorders. Front Aging Neurosci (2016) 0.75
Seeding and transgenic overexpression of alpha-synuclein triggers dendritic spine pathology in the neocortex. EMBO Mol Med (2017) 0.75
Alpha-synuclein modulates dopamine neurotransmission. J Chem Neuroanat (2016) 0.75
α-synuclein interacts with PrP(C) to induce cognitive impairment through mGluR5 and NMDAR2B. Nat Neurosci (2017) 0.75
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med (2005) 4.34
Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science (2003) 2.89
The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One (2010) 2.78
Imaging distinct conformational states of amyloid-beta fibrils in Alzheimer's disease using novel luminescent probes. ACS Chem Biol (2007) 2.18
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech (2009) 2.16
Age-related somatic structural changes in the nuclear genome of human blood cells. Am J Hum Genet (2012) 2.15
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol (2003) 1.99
Cell-penetrating peptides and antimicrobial peptides: how different are they? Biochem J (2006) 1.92
Uniform polarity microtubule assemblies imaged in native brain tissue by second-harmonic generation microscopy. Proc Natl Acad Sci U S A (2003) 1.81
Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. Nat Rev Microbiol (2009) 1.79
Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A (2006) 1.73
APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. Exp Neurol (2003) 1.73
Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering. Proc Natl Acad Sci U S A (2010) 1.72
Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci (2004) 1.63
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
From antimicrobial to anticancer peptides. A review. Front Microbiol (2013) 1.56
Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett (2007) 1.54
The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging (2005) 1.53
Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog Neurobiol (2007) 1.50
Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem (2007) 1.46
Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol (2008) 1.46
Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol (2005) 1.45
Quantifying molecular partition into model systems of biomembranes: an emphasis on optical spectroscopic methods. Biochim Biophys Acta (2003) 1.32
No association between CALHM1 and Alzheimer's disease risk. Cell (2008) 1.30
In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging (2007) 1.29
Escherichia coli cell surface perturbation and disruption induced by antimicrobial peptides BP100 and pepR. J Biol Chem (2010) 1.27
Caffeine and adenosine. J Alzheimers Dis (2010) 1.25
Expression of APP pathway mRNAs and proteins in Alzheimer's disease. Brain Res (2007) 1.25
Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord (2009) 1.23
Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem (2010) 1.22
Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J Biol Chem (2007) 1.22
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm (Vienna) (2009) 1.22
Sexually dimorphic effect of the Val66Met polymorphism of BDNF on susceptibility to Alzheimer's disease: New data and meta-analysis. Am J Med Genet B Neuropsychiatr Genet (2010) 1.20
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. J Alzheimers Dis (2010) 1.19
Polymorphisms in the SCD1 gene: associations with body fat distribution and insulin sensitivity. Obesity (Silver Spring) (2007) 1.18
The common FTO variant rs9939609 is not associated with BMI in a longitudinal study on a cohort of Swedish men born 1920-1924. BMC Med Genet (2009) 1.16
Physiochemical characterization of the Alzheimer's disease-related peptides A beta 1-42Arctic and A beta 1-42wt. FEBS J (2006) 1.14
Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms. Exp Neurol (2005) 1.14
Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study. J Alzheimers Dis (2009) 1.12
Evaluation of lipopolysaccharide aggregation by light scattering spectroscopy. Chembiochem (2003) 1.11
Loss of astrocyte polarization in the tg-ArcSwe mouse model of Alzheimer's disease. J Alzheimers Dis (2011) 1.11
Translocation of beta-galactosidase mediated by the cell-penetrating peptide pep-1 into lipid vesicles and human HeLa cells is driven by membrane electrostatic potential. Biochemistry (2005) 1.10
The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol (2010) 1.09
The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neurosci Lett (2007) 1.09
Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J (2009) 1.08
An overview of the biophysical applications of atomic force microscopy. Biophys Chem (2004) 1.07
Animal models of amyloid-beta-related pathologies in Alzheimer's disease. FEBS J (2010) 1.06
An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol Dis (2009) 1.06
Decrease of adenosine A1 receptor density and of adenosine neuromodulation in the hippocampus of kindled rats. Eur J Neurosci (2003) 1.06
Decoding the membrane activity of the cyclotide kalata B1: the importance of phosphatidylethanolamine phospholipids and lipid organization on hemolytic and anti-HIV activities. J Biol Chem (2011) 1.06
rBPI(21) promotes lipopolysaccharide aggregation and exerts its antimicrobial effects by (hemi)fusion of PG-containing membranes. PLoS One (2009) 1.06
A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog (2013) 1.05
Transcriptional up-regulation and activation of initiating caspases in experimental glaucoma. Am J Pathol (2005) 1.05
What can light scattering spectroscopy do for membrane-active peptide studies? J Pept Sci (2008) 1.05
Design and characterization of novel antimicrobial peptides, R-BP100 and RW-BP100, with activity against Gram-negative and Gram-positive bacteria. Biochim Biophys Acta (2012) 1.04
Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease. Comb Chem High Throughput Screen (2005) 1.04
Dengue virus capsid protein binding to hepatic lipid droplets (LD) is potassium ion dependent and is mediated by LD surface proteins. J Virol (2011) 1.04
SIRT2 as a Therapeutic Target for Age-Related Disorders. Front Pharmacol (2012) 1.04
Heparan sulfate mediates amyloid-beta internalization and cytotoxicity. Glycobiology (2010) 1.04
Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One (2011) 1.04
Pen-2 is sequestered in the endoplasmic reticulum and subjected to ubiquitylation and proteasome-mediated degradation in the absence of presenilin. J Biol Chem (2004) 1.03
The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of α-synuclein oligomers with distinct biochemical, morphological, and functional properties. Free Radic Biol Med (2010) 1.03
Genetic analysis of Alzheimer's disease in the Uppsala Longitudinal Study of Adult Men. Dement Geriatr Cogn Disord (2009) 1.02
Single molecule profiling of tau gene expression in Alzheimer's disease. J Neurochem (2007) 1.02
A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice. Neurobiol Aging (2008) 1.02
The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. J Neurochem (2007) 1.02
Sensitive detection of Aβ protofibrils by proximity ligation--relevance for Alzheimer's disease. BMC Neurosci (2010) 1.02
Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice. Neurobiol Aging (2011) 1.01
Visualization of cell-to-cell transmission of mutant huntingtin oligomers. PLoS Curr (2011) 1.01
Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid (2003) 1.00
The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation. EMBO J (2013) 0.99
Extended investigation of tau and mutation screening of other candidate genes on chromosome 17q21 in a Swedish FTDP-17 family. Am J Med Genet B Neuropsychiatr Genet (2003) 0.99
Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol (2008) 0.98
Alpha-synuclein and chaperones in dementia with Lewy bodies. J Neuropathol Exp Neurol (2005) 0.98
Vascular risk factors and dementia: 40-year follow-up of a population-based cohort. Dement Geriatr Cogn Disord (2011) 0.97
The tau R406W mutation causes progressive presenile dementia with bitemporal atrophy. Dement Geriatr Cogn Disord (2004) 0.97
Omiganan interaction with bacterial membranes and cell wall models. Assigning a biological role to saturation. Biochim Biophys Acta (2007) 0.97
Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. J Alzheimers Dis (2013) 0.97
Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid. Neurodegener Dis (2009) 0.97
Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells. Brain Pathol (2008) 0.97